Valuation: Guided Therapeutics, Inc.

Market Cap 13.97M 12.51M 11.51M 10.43M 19.49M 1.33B 19.85M 137M 55.08M 698M 52.42M 51.31M 2.2B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 16.84M 15.09M 13.88M 12.57M 23.5M 1.6B 23.94M 165M 66.43M 841M 63.21M 61.87M 2.65B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
09-10 Guided Therapeutics, Inc. and Türkiye Ministry of Health Reach Collaborative Agreement for Primary Screening Test for Cervical Cancer CI
08-14 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-15 Guided Therapeutics, Inc. Announces New Agreement With Yuanshuo Medical Instruments Corporation CI
06-16 Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA CI
05-16 Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-31 Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
12-18 Guided Therapeutics, Inc. Announces Preliminary Findings from Its FDA Pivotal Clinical Trial CI
12-12 Guided Therapeutics, Inc. Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor CI
11-19 Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation CI
11-14 Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
19/08/25 Guided Therapeutics, Inc. Receives $70,000 from New Chinese Distribution Partner That Provides Products for 2 Million Annual Cervical Cancer Screenings CI
15/08/25 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 week+34.71%
Current month-7.62%
1 month+14.50%
3 months-23.67%
6 months+14.50%
Current year-57.59%
1 week 0.13
Extreme 0.1319
0.23
1 month 0.13
Extreme 0.1319
0.24
Current year 0.13
Extreme 0.1319
0.54
1 year 0.13
Extreme 0.1319
0.54
3 years 0.06
Extreme 0.064
0.54
5 years 0.06
Extreme 0.062
0.78
10 years 0.02
Extreme 0.0206
3,200
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 70 01/12/2016
Director/Board Member 76 10/04/2006
Chairman 67 01/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
10/3/26 Free

Chairman

110,000 0.1316%
10/3/26 Others

Director

466,991 0.5586%
10/3/26 Free

Director

110,000 0.1316%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+34.71%-0.43%+37.13% 13.97M
-1.72%+3.44%+25.31%+60.56% 262B
-2.00%+0.75%+7.99%+25.46% 167B
-3.73%-4.48%-18.49%+67.13% 156B
-1.66%-8.12%-58.26%-16.12% 61.87B
-2.57%+3.30%+10.22%+47.55% 54.44B
0.00%+2.71%-13.09%-6.48% 53.3B
-3.47%+1.04%+21.98%+72.85% 51.07B
+0.84%-3.12%+9.80%+64.47% 50.25B
-3.61%+1.99%+34.94%+95.49% 47.17B
Average -1.59%+1.52%+2.00%+44.80% 90.26B
Weighted average by Cap. -1.63%+2.44%+5.11%+47.95%

Financials

2024 2025
Net sales 7K 6.27K 5.77K 5.23K 9.77K 665K 9.95K 68.77K 27.61K 350K 26.27K 25.71K 1.1M 767K 687K 632K 573K 1.07M 72.83M 1.09M 7.54M 3.02M 38.31M 2.88M 2.82M 121M
Net income -2.42M -2.16M -1.99M -1.8M -3.37M -229M -3.44M -23.74M -9.53M -121M -9.07M -8.88M -381M -3.2M -2.86M -2.63M -2.39M -4.46M -303M -4.54M -31.4M -12.6M -160M -11.99M -11.74M -503M
Net Debt 1.77M 1.59M 1.46M 1.32M 2.47M 168M 2.52M 17.4M 6.98M 88.46M 6.65M 6.51M 279M 2.88M 2.58M 2.37M 2.15M 4.01M 273M 4.09M 28.25M 11.34M 144M 10.79M 10.56M 453M
Projected Income Statement - Annual - Guided Therapeutics, Inc.
Logo Guided Therapeutics, Inc.
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
3
Date Price Change Volume
29/10/26 US$0.1447 -1.69% 1,000
28/10/26 US$0.1472 +1.48% 1,951
27/10/26 US$0.1450 +9.95% 1,127
26/10/26 US$0.1319 -9.03% 1,003
23/10/26 US$0.1450 -14.71% 10,272
  1. Stock Market
  2. Stocks
  3. GTHP Stock